Skip to main content
SpringerLink
Log in

Effects of ritanserin, a novel serotonin-s2 receptor antagonist, on the secretion of pituitary hormones in normal humans

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The availability of a new potent and selective serotonin-S2 antagonist, ritanserin (RIT), encouraged us to further investigate the effect of serotonin on the basal secretion of anterior pituitary hormones in normal humans. Administered in a single 30-mg dose to group 1 consisting of 10 normal women, RIT failed to affect the baseline LH, FSH, GH or TSH levels. In group 2 consisting of 20 normal subjects (ten males and ten females), the same dose of RIT decreased in parallel both ACTH and Cortisol levels but only at 180 min. Group 3 consisting of 8 normal men was studied on three separate occasions seven days apart: each subject received graded doses of 10 mg, 20 mg and 30 mg RIT. The mean baseline PRL concentration at 180 min as well as the net integrated area under the hormone curve (nAUC) decreased only after the highest dose, while the baseline Cortisol concentrations at 180 min as well as the corresponding nAUC values displayed a clear dose-dependent response. The findings indicated the serotonin-S2 receptors to be only partially involved in the basal secretion of ACTH in normal humans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Delitala G., Masala A., Alagna S., Devilla L. Effect of cyproheptadine on the spontaneous diurnal variations of plasma ACTH-cortisol and ACTHGH secretion induced by L-DOPA. Biomed. (Express) 23: 406, 1975.

    CAS  Google Scholar 

  2. Cavagnini F., Raggi U., Micossi P., Di Landro A., Invitti C. Effect of an antiserotoninergic drug, metergoline, on the ACTH and Cortisol response to insulin hypoglycemia and lysine-vasopressin in man. J. Clin. Endocrinol. Metab. 43: 306, 1976.

    Article  PubMed  CAS  Google Scholar 

  3. Lewis D.A., Sherman B.M. Serotoninergic stimulation of adrenocorticotropin secretion in man. J. Clin. Endocrinol. Metab. 58: 458, 1984.

    Article  PubMed  CAS  Google Scholar 

  4. Plonk J.W., Bivens C.H., Feldman J.M. Inhibition of hypoglycemia-induced Cortisol secretion by the serotonin antagonist cyproheptadine. J. Clin. Endocrinol. Metab. 38: 836, 1974.

    Article  PubMed  CAS  Google Scholar 

  5. Kletzky O.A., Marrs R.P., Nicoloff J.T. Effects of cyproheptadine on insulin-induced hypoglycemia secretion of PRL, GH and Cortisol. Clin. Endocrinol. (Oxf.) 73: 231, 1980.

    Article  Google Scholar 

  6. Bivens C.H., Lebovitz H.E., Feldman J.M. Inhibition of hypoglycemia-induced growth hormone secretion by serotonin antagonists cyproheptadine and methysergide. N. Engl. J. Med. 289: 236, 1973.

    Article  PubMed  CAS  Google Scholar 

  7. Ferrari C, Paracchi A., Rondena M., Beck-Peccoz P., Faglia G. Effect of two serotonin antagonists on prolactin and thyrotrophin secretion in man. Clin. Endocrinol. (Oxf.) 5: 575, 1976.

    Article  CAS  Google Scholar 

  8. Egge A.C., Rogol A.D., Varma M.M., Blizzard R.M. Effect of cyproheptadine on TRH-stimulated prolactin and TSH release in man. J. Clin. Endocrinol. Metab. 44: 210, 1977.

    Article  PubMed  CAS  Google Scholar 

  9. Golstein J., Vanhaelst L, Bruno O.D., L’Hermite M. Effect of cyproheptadine on thyrotropin and prolactin secretion in normal man. Acta Endocr. (Copenh) 92: 205, 1979.

    CAS  Google Scholar 

  10. Peroutka S.J., Snyder S.H. Multiple serotonin receptors: differential binding of 5-hydroxytryptamine (3H) lysergic acid diethylamide and (3H) spiroperidol. Mol. Pharmacol, 16: 687, 1979.

    PubMed  CAS  Google Scholar 

  11. Leysen J.E., Awouters F., Kennis L, Laduron P.M., Vandenber J., Janssen P.A.J. Receptor binding profile of R-41-468, a novel antagonist at 5-HT2 receptors. Life Sci. 23: 1015, 1981.

    Article  Google Scholar 

  12. Leysen J.E., Gommeren W., Van Gompel P., Wynants J., Janssen P.F., Laduron P.M. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Mol. Pharmacol. 27: 600, 1985.

    PubMed  CAS  Google Scholar 

  13. Zoccali C., Zabludowski J.R., Isles C.G., Murray G.D., Inglis G.C., Robertson J.I.S., Fraser R., Ball S.G. The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in normal man. Br. J. Clin. Pharmacol. 16: 306, 1983.

    Article  Google Scholar 

  14. Gordin A., Mustajoki P., Pelkonen R. Ketanserin without effects on basal anterior pituitary hormone secretion in healthy subjects. J. Endocrinol. Invest. 8: 73, 1985.

    Article  PubMed  CAS  Google Scholar 

  15. Rocco A., De Giorgio G., Buongiorno T., Proietti A., Lucchetti G., Falaschi P. Prolactin response to R41468, a new specific 5HT-2 antagonist. Neuroendocrinol. Lett. 5: 47, 1983.

    CAS  Google Scholar 

  16. O’Malley B.P., Jennings P.E., Cook N., Barnett D.B., Rosenthal F.D. The role of serotonin (5-HT) in the control of TSH and prolactin release in euthyroid subjects as assessed by the administration of ketanserin (5-HT2 antagonist) and zimelidine (5-HT re-uptake inhibitor). Psychoneuroendocrinology 9: 13, 1984.

    Article  PubMed  Google Scholar 

  17. Falaschi P., Rosa M., Rocco A., D’Urso R., Proietti A., Melis G.B. Effect of Ritanserin, specific 5HT-2 antagonist, on PRL secretion in normal subjects and in different hyperprolactinaemic conditions. Clin. Endocrinol. (Oxf.) 34: 449, 1991.

    Article  CAS  Google Scholar 

  18. Delitala G., Masala A., Alagna S., Devilla L., Rovasio P.P. Inhibition of prolactin release by metergoline administration in man. Biomed. (Express) 27: 31, 1977.

    CAS  Google Scholar 

  19. Krulich L, McCann S.M., Mayfield M.A. On the mode of the prolactin release-inhibiting action of the serotonin receptor blockers metergoline, methysergide and cyproheptadine. Endocrinology 708: 1115, 1981.

    Article  Google Scholar 

  20. Lesch K.P., Söhnle K., Poten B., Schoellnhammer G., Rupprecht R., Schulte H.M. Corticotropin and Cortisol secretion after central 5-hydroxytryptamine-1A (5-HT1A receptor activation: effects of 5-HT receptor and beta-adrenoceptor antagonist. J. Clin. Endocrinol. Metab. 70: 670, 1990.

    Article  PubMed  CAS  Google Scholar 

  21. Krieger D.T., Rizzo F. Serotonin mediation of circadian periodicity of plasma 17-hydroxycorticosteroids. Am. J. Physiol. 217: 1703, 1969.

    PubMed  CAS  Google Scholar 

  22. Reghunandanan V., Reghunandanan R., Marya R.K. Vasopressin: its possible role in circadian time keeping. Chronobiologia 18: 39, 1991.

    PubMed  CAS  Google Scholar 

  23. Prescott R.W., Kendall-Taylor P., Weightman D.R., Watson M.J., Ratcliffe W.A. The effect of ketanserin, a specific serotonin antagonist on the PRL, GH, ACTH and Cortisol responses to hypoglycaemia in normal subjects. Clin. Endocrinol. (Oxf.) 20: 137, 1984.

    Article  CAS  Google Scholar 

  24. Facchinetti F., Martignoni E., Nappi G., Marini S., Petraglia F., Sandrini G., Genazzani A.R. Ritanserin, a serotonin-S2 receptor antagonist, does not prevent 5-hydroxytryptophan-induced beta-EP, beta LPH and Cortisol secretion. Hormone Res. 27: 42, 1987.

    Article  PubMed  CAS  Google Scholar 

  25. Lee M.A., Nash J.F., Barnes M., Meitzer H.Y. Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated Cortisol, ACTH and prolactin secretion in humans. Psychopharmacology (Berl.) 103: 253, 1991.

    Article  Google Scholar 

  26. Uretsky N.J., Iversen L.L. Effects of 6-hydroxy-dopamine on catecholamine containing neurons in the rat brain. J. Neurochem. 17: 269, 1970.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Department of Internal Medicine, Zagreb University School of Medicine, Zagreb Clinical Center, Kišpaticeva 12, 41000, Zagreb, Croatia

    Danilo Tepavčević, Z. Giljević, M. Korşić, S. Halimi, E. Suchanek, T. Jelić, I. Aganović, B. Kožić & V. Plavşić

Authors
  1. Danilo Tepavčević
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Giljević
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Korşić
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Halimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Suchanek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Jelić
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I. Aganović
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B. Kožić
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. V. Plavşić
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tepavčević, D., Giljević, Z., Korşić, M. et al. Effects of ritanserin, a novel serotonin-s2 receptor antagonist, on the secretion of pituitary hormones in normal humans. J Endocrinol Invest 17, 1–5 (1994). https://doi.org/10.1007/BF03344953

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344953

Key-words

Search

Navigation